RPS6KB2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1086146	0.63	7/20
SCHEMBL2860819	0.53	7/20
SCHEMBL1900702	0.67	6/20
SCHEMBL578071	0.61	6/20
SCHEMBL578070	0.58	6/20
SCHEMBL2218274	0.50	6/20
SCHEMBL2858919	0.46	6/20
Hydrochloric Acid (SCHEMBL311235)	0.63	5/20
SCHEMBL311609	0.62	5/20
Hydrochloric Acid (SCHEMBL312002)	0.60	5/20
SCHEMBL310924	0.58	5/20
SCHEMBL1128864	0.58	5/20
SCHEMBL820251	0.50	5/20
SCHEMBL3682427	0.45	5/20
SCHEMBL1898657	0.42	5/20
SCHEMBL472804	0.42	5/20
SCHEMBL2965386	0.41	5/20
Hydrochloric Acid (SCHEMBL312213)	0.74	4/20
Hydrochloric Acid (SCHEMBL311202)	0.61	4/20
SCHEMBL1458743	0.57	4/20

Clinical trials — most relevant to RPS6KB2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle	PHASE2	NOT_YET_RECRUITING
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma	PHASE1/PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)	PHASE1/PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI	PHASE2	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Exercise Effects on Cardiometabolic Health and Sestrin-2 in Hypertensive Obese Women	nan	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED
NK Cell Deregulation in HBV Patients	nan	ACTIVE_NOT_RECRUITING
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)	nan	RECRUITING
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPS6KB2 binder may also engage these)

Protein	Name	Similarity
Q9Z1M4	—	0.999	Q9Z1M4 →
RPS6KB1	Ribosomal protein S6 kinase beta-1	0.994	landscape →
Q8BSK8	—	0.994	Q8BSK8 →
Q6TJY3	—	0.994	Q6TJY3 →
O19111	—	0.992	O19111 →
P67998	—	0.989	P67998 →
PHKG2	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	0.988	landscape →
Q6PFQ0	—	0.987	Q6PFQ0 →
Q9NBK5	—	0.987	Q9NBK5 →
Q63531	—	0.987	Q63531 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	0.987	landscape →
Q8C050	—	0.986	Q8C050 →
P67999	—	0.986	P67999 →
Q39030	—	0.986	Q39030 →
Q02956	—	0.986	Q02956 →
Q8BRK8	—	0.986	Q8BRK8 →
PRKCZ	Protein kinase C zeta type	0.985	landscape →
Q5R4K9	—	0.985	Q5R4K9 →
Q12706	—	0.985	Q12706 →
Q9JJX8	—	0.985	Q9JJX8 →
Q62074	—	0.984	Q62074 →
P18653	—	0.984	P18653 →
STK32C	Serine/threonine-protein kinase 32C	0.984	landscape →
Q4G050	—	0.984	Q4G050 →
P10665	—	0.984	P10665 →
P13234	—	0.984	P13234 →
MKNK1	MAP kinase-interacting serine/threonine-protein kinase 1	0.984	landscape →
O08605	—	0.984	O08605 →
F1M7Y5	—	0.983	F1M7Y5 →
Q2LZZ7	—	0.983	Q2LZZ7 →